GlassScriptPhysician profile
Kimberly E Cook
NPI 1982370029
$2,880.55
in general payments reported to CMS, 2019-2025
30 companies · $20.92 in 2025
The $20.92 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.93 · 2022: $1,328 · 2023: $952 · 2024: $563 · 2025: $20.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.16 | 2022-2025 | |
| Lilly USA, LLC | $345.75 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $223.07 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $219.87 | 2022-2024 | Trintellix |
| Novo Nordisk INC | $215.29 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $186.12 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $155.33 | 2022-2024 | |
| Amgen INC. | $149.46 | 2022-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.86 | 2022-2023 | Jardiance |
| Pfizer INC. | $86.71 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $77.21 | 2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $75.82 | 2022-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $65.71 | 2022-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Esperion Therapeutics, INC. | $62.66 | 2022-2024 | Nexletol |
| Tris Pharma INC | $53.32 | 2023-2024 | Dyanavel Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $49.38 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $43.85 | 2022-2023 | Qelbree |
| Sumitomo Pharma America, INC. | $43.30 | 2023-2024 | Gemtesa |
| Abbott Laboratories | $36.86 | 2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $32.02 | 2022-2023 | Myrbetriq |
| Exact Sciences Corporation | $31.21 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $28.10 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $26.21 | 2024 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $22.91 | 2022 | |
| Shield Therapeutics INC | $22.87 | 2024 | |
| Insulet Corporation | $19.84 | 2023 | Omnipod |
| Lundbeck LLC | $18.60 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.43 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.93 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.